Drug Trial Radar · NCT04967664
Comparison of Qutenza (8% Capsaicin) With a Low-dose Capsaicin for Treatment of Nerve Pain After Surgery
Last checked: Nov 20, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
412
Actual
Start
Jul 13, 2021
Primary completion
Aug 28, 2025
Study completion Aug 28, 2025
Sponsor
- Lead sponsor
- Averitas Pharma, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 19, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an interventional, Phase III, double-blind, randomized, controlled, parallel-group, multi-site, clinical trial to confirm the efficacy and safety of repeated topical application of Qutenza (capsaicin 8% topical system) versus low-dose capsaicin control (capsaicin 0.04% topical system) in subjects with moderate to severe postsurgical neuropathic pain (PSNP).
Conditions
- Post Surgical Neuropathic Pain
Interventions
Qutenza (capsaicin) 8% topical systemDrug
High concentration capsaicin
capsaicin 0.04% topical systemDrug
Low-dose capsaicin control
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in the 24-Hour Average Pain Intensity (API) Between Week 2 and Week 12 [Core Phase]Time frame: From the Baseline Phase (Day -7 to Day -1) to Visit 6 (Week 12/Day 84).
- Change From Baseline in the 24-Hour API to Week 12 [Core Phase]Time frame: From the Baseline Phase (Day -7 to Day -1) to Visit 6 (Week 12/Day 84).
Locations
64 sites in 6 countries. Site status is shown where the registry gives one.
Tucson Orthopaedic Institute
Tucson, Arizona
ILD Research Center
Vista, California
International Spine, Pain, and Performance Center
Washington D.C., District of Columbia
South Lake Pain Institute
Clermont, Florida
University Clinical Research - DeLand Clinical Research Unit
DeLand, Florida
Florida Research Center, Inc.
Miami, Florida
Clinical Research of West Florida
Tampa, Florida
Drug Studies America
Marietta, Georgia
Rush University Medical Center
Chicago, Illinois
Neuroscience Research Center, LLC
Overland Park, Kansas
Kansas City Bone & Joint Clinic, P.A.
Overland Park, Kansas
Boston Clinical Trials
Boston, Massachusetts
Great Lakes Research Group, Inc.
Bay City, Michigan
Premier Pain Centers
Shrewsbury, New Jersey
Ainsworth Institute of Pain Management
New York, New York
Accellacare
Wilmington, North Carolina
The Center for Clinical Research
Winston-Salem, North Carolina
META Medical Research Institute, LLC
Dayton, Ohio
Main Line Spine
King of Prussia, Pennsylvania
New Phase Research & Development
Knoxville, Tennessee
Expert Pain
Houston, Texas
The University of Texas Health Science Center at San Antonio
San Antonio, Texas
Wasatch Clinical Research, LLC
Salt Lake City, Utah
CHU Amiens Picardie
Amiens, France
Centre Regional De Lutte Contre Le Cancer (Crlcc) -Centre Paul Papin
Angers, France
Centre Hospitalier Jean Rougier
Cahors, France
Centre Hospitalier Universitaire de Clermont Ferrand
Clermont-Ferrand, France
Centre Hospitalier Regional Universitaire (CHRU) de Lille - Hopital Claude Huriez
Lille, France
Clinique Francois Chenieux
Limoges, France
Cochin Hospital-Paris Descartes University
Paris, France
Groupe Hospitalier Paris saint-Joseph
Paris, France
CHU Poitiers / La Miletrie
Poitiers, France
Centre Hospitalier Departemental Vendee - Centre d'evaluation et de Traitement de la Douleur
La Roche-sur-Yon, Pays de la Loire Region, France
CHU de Nantes - Hopital Nord Laennec
Nantes, Pays de la Loire Region, France
VUMC
Amsterdam, Netherlands
PT&R
Beek, Netherlands
NOCEPTA
Hengelo, Netherlands
Leiden University Medical Center (LUMC)
Leiden, Netherlands
Vitamed Nzoz Im. Edyty Jakubow
Bialystok, Poland
Nzoz Neuro-Medic
Katowice, Poland
Showing 40 of 64 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.